Lessons learnt from 1300 consecutive gallbladder cancer surgeries : Evolving role of peri-operative chemotherapy in the treatment paradigm
© 2023 Published by Elsevier Ltd..
BACKGROUND: Level I evidence for multi-modality management of gallbladder cancers (GBC) is evolving.
METHODS: Prospectively maintained operative GBC database of 1307 patients (year 2010-2019) was analysed to study the impact of peri-operative chemotherapy (PCT) on survival outcomes.
RESULTS: 1040 patients had pathologically confirmed GBC. Stage distribution showed: Stage I(85,8.2%), II(247,23.8%), III(460,44.2%), IV(248, 23.8%). PCT was used as follows: in stage II, 164 patients received adjuvant chemotherapy(ACT); in stage III, ACT was given to 444 patients, either operated upfront(244 patients) or after neoadjuvant chemotherapy (NACT)(216 patients); in stage IV, 32 patients (11 received NACT) underwent radical surgery followed by ACT and 216 patients had inoperable disease (77 received NACT) upon exploration. With a median follow-up of 30 months, the 3-year OS for stage I, II and III was 94.1%, 82.6% and 48.2% respectively. Corresponding DFS was 93.8%, 67.3% and 38.3%. Upon reassessment for surgery after NACT (n = 332), patients who underwent radical surgery (n = 235) had superior OS (p = 0.000) and DFS (p = 0.000) in comparison to those who had inoperable disease (n = 97). Amongst stage III and IV patients with operable disease (n = 492), those who were operated upfront (n = 238) had equivalent survival as those operated after NACT (n = 254). This was also confirmed by a 1:1 propensity matched analysis (118 patients each), matching for T and N stage.
CONCLUSION: The role of peri-operative chemotherapy in management of GBC is evolving. While the role of NACT for locally advanced GBC is unsettled and merits testing prospectively, it helps in selection of patients with favourable disease biology for radical surgery.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - 49(2023), 10 vom: 01. Okt., Seite 107035 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patkar, Shraddha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Gallbladder cancer |
|---|
| Anmerkungen: |
Date Revised 30.09.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.ejso.2023.107035 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361027133 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361027133 | ||
| 003 | DE-627 | ||
| 005 | 20231226084257.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejso.2023.107035 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM361027133 | ||
| 035 | |a (NLM)37604098 | ||
| 035 | |a (PII)S0748-7983(23)00673-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patkar, Shraddha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lessons learnt from 1300 consecutive gallbladder cancer surgeries |b Evolving role of peri-operative chemotherapy in the treatment paradigm |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2023 Published by Elsevier Ltd. | ||
| 520 | |a BACKGROUND: Level I evidence for multi-modality management of gallbladder cancers (GBC) is evolving | ||
| 520 | |a METHODS: Prospectively maintained operative GBC database of 1307 patients (year 2010-2019) was analysed to study the impact of peri-operative chemotherapy (PCT) on survival outcomes | ||
| 520 | |a RESULTS: 1040 patients had pathologically confirmed GBC. Stage distribution showed: Stage I(85,8.2%), II(247,23.8%), III(460,44.2%), IV(248, 23.8%). PCT was used as follows: in stage II, 164 patients received adjuvant chemotherapy(ACT); in stage III, ACT was given to 444 patients, either operated upfront(244 patients) or after neoadjuvant chemotherapy (NACT)(216 patients); in stage IV, 32 patients (11 received NACT) underwent radical surgery followed by ACT and 216 patients had inoperable disease (77 received NACT) upon exploration. With a median follow-up of 30 months, the 3-year OS for stage I, II and III was 94.1%, 82.6% and 48.2% respectively. Corresponding DFS was 93.8%, 67.3% and 38.3%. Upon reassessment for surgery after NACT (n = 332), patients who underwent radical surgery (n = 235) had superior OS (p = 0.000) and DFS (p = 0.000) in comparison to those who had inoperable disease (n = 97). Amongst stage III and IV patients with operable disease (n = 492), those who were operated upfront (n = 238) had equivalent survival as those operated after NACT (n = 254). This was also confirmed by a 1:1 propensity matched analysis (118 patients each), matching for T and N stage | ||
| 520 | |a CONCLUSION: The role of peri-operative chemotherapy in management of GBC is evolving. While the role of NACT for locally advanced GBC is unsettled and merits testing prospectively, it helps in selection of patients with favourable disease biology for radical surgery | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Gallbladder cancer | |
| 650 | 4 | |a High-quality surgery | |
| 650 | 4 | |a Locally advanced | |
| 650 | 4 | |a Neoadjuvant chemotherapy | |
| 650 | 4 | |a Radical cholecystectomy | |
| 700 | 1 | |a Patel, Swapnil |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Ostwal, Vikas |e verfasserin |4 aut | |
| 700 | 1 | |a Ramaswamy, Anant |e verfasserin |4 aut | |
| 700 | 1 | |a Shetty, Nitin |e verfasserin |4 aut | |
| 700 | 1 | |a Goel, Mahesh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology |d 1993 |g 49(2023), 10 vom: 01. Okt., Seite 107035 |w (DE-627)NLM01262862X |x 1532-2157 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2023 |g number:10 |g day:01 |g month:10 |g pages:107035 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejso.2023.107035 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2023 |e 10 |b 01 |c 10 |h 107035 | ||